Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Rivaroxaban
Drug ID BADD_D01954
Description Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.
Indications and Usage Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurrent DVT and/or PE. Rivaroxaban is also indicated, in combination with aspirin, for reducing the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease. Its use is also not recommended in those with severe renal impairment (<30mL/min).[L12819] Rivaroxaban is also indicated for the treatment and prevention of VTE in pediatric patients (from birth to 18 years of age) and for thromboprophylaxis in pediatric patients ≥2 years old with congenital heart disease following the Fontan procedure.[L12819]
Marketing Status approved
ATC Code B01AF01
DrugBank ID DB06228
KEGG ID D07086
MeSH ID D000069552
PubChem ID 9875401
TTD Drug ID D0KG3R
NDC Product Code 66174-0087; 69218-0500; 50458-577; 53296-0109; 63415-0523; 64552-4049; 65862-971; 66039-913; 71610-690; 75945-050; 76072-1008; 86051-002; 14501-0079; 16436-0109; 86051-004; 50458-578; 50458-579; 50458-580; 50458-584; 55154-1422; 55111-966; 50458-575; 14799-2023; 58032-2029; 65015-898; 65977-0139; 86051-001; 55154-1423; 12658-0516; 53747-068; 83137-0007; 53104-7730; 59285-009; 65727-050; 47848-039; 52286-0025; 64220-176; 65372-1193; 66022-0203; 86051-003; 55154-1424; 62512-0079; 82513-0001
UNII 9NDF7JZ4M3
Synonyms Rivaroxaban | 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide | Xarelto | BAY 59-7939 | BAY 59 7939 | BAY 597939
Chemical Information
Molecular Formula C19H18ClN3O5S
CAS Registry Number 366789-02-8
SMILES C1COCC(=O)N1C2=CC=C(C=C2)N3CC(OC3=O)CNC(=O)C4=CC=C(S4)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lacunar infarction24.04.06.009; 17.08.01.0160.000475%Not Available
Catheter site haemorrhage24.07.01.003; 12.07.02.002; 08.02.02.0020.000690%Not Available
Puncture site haemorrhage12.07.04.006; 24.07.01.034; 08.02.04.0070.000190%Not Available
Facial paresis17.04.03.0020.000348%
Exercise tolerance decreased08.01.03.0360.000298%Not Available
Wound haemorrhage24.07.01.029; 12.01.08.017--Not Available
Rhinalgia22.12.03.0200.000063%Not Available
Large intestine polyp16.05.02.006; 07.20.01.0100.001070%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.0150.001235%Not Available
Skin induration23.03.03.0200.000095%
Haemodynamic instability24.03.02.0060.000728%Not Available
Oesophageal rupture12.01.17.015; 07.04.05.0050.000127%Not Available
Lymphatic disorder01.09.01.0030.000063%Not Available
Large intestinal haemorrhage24.07.02.026; 07.12.03.0030.001045%
Urticaria chronic23.04.02.009; 10.01.06.0090.000063%Not Available
Cardiac flutter02.03.02.012--Not Available
Ocular vascular disorder06.07.02.002; 24.03.07.0050.000063%Not Available
Epigastric discomfort07.01.02.0040.000456%Not Available
Eyelid bleeding23.06.07.005; 06.07.05.001; 24.07.05.0100.000063%Not Available
Vascular occlusion24.04.02.0150.000329%Not Available
Vascular rupture24.03.02.023; 12.01.11.0060.000285%Not Available
Acquired haemophilia01.01.01.0020.000127%Not Available
Cerebral haematoma24.07.04.006; 17.08.01.0140.002749%Not Available
Dacryostenosis acquired06.06.04.0030.000095%Not Available
Vessel puncture site haemorrhage12.07.04.014; 08.02.04.014; 24.07.01.0610.000279%Not Available
Cardiac discomfort02.11.04.0010.000158%Not Available
Haemorrhoidal haemorrhage24.10.02.001; 07.15.03.0020.004858%
Mucosal discolouration08.01.06.0080.000063%Not Available
Pelvic haematoma24.07.03.010; 21.07.04.0010.000361%Not Available
Hepatic cancer metastatic16.07.02.002; 09.04.02.0060.000063%Not Available
The 16th Page    First    Pre   16 17 18 19 20    Next   Last    Total 29 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene